Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia

Bernhard Rauch

History of progress in dual pathway inhibition in cardiovascular disease

In an attempt to optimise long-term prevention against adverse events in patients with cardiovascular disease (CVD) several antithrombotic regimens have been tested as potential alternatives to single medication with low dose aspirin, but initially a convincing improvement of the benefit–risk ratio has not been achieved.1–5 In the ATLAS ACS 2–TIMI 51 trial (“Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome -thrombolysis in myocardial infarction 51”), however, the addition of low dose rivaroxaban (2.5 mg twice daily) to standard medication in patients after surviving an acute coronary syndrome (ACS) was associated with a significant reduction of mortality along a mean treatment period of 13.3 months.6

A beneficial effect of rivaroxaban 2 × 2.5 mg daily in combination with aspirin (100 mg daily; dual pathway inhibition; DPI) thereafter was confirmed by the COMPASS trial (“Cardiovascular Outcomes for People Using Anticoagulation Strategies”) evaluating clinically stable patients with coronary artery disease (CAD)7 as well as patients with stable peripheral artery disease (PAD) or carotid artery disease.8 In stable CAD as well as in PAD patients, DPI was associated with a significantly reduced occurrence of the primary endpoint defined as a composite of cardiovascular death, myocardial infarction or stroke.7,8 Moreover, in PAD patients the additional primary endpoint defined as ‘major adverse limb events including major amputation’ was also significantly reduced by DPI.8

Benefit risk analysis of DPI

Notably, in CAD as well as in PAD patients the beneficial effect of DPI was demonstrated in a considerable number of subgroups including high-risk patients with diabetes and/or current smokers.7,8 Not surprisingly, however, these cardiovascular benefits were accompanied by a significant increase of ‘major bleeding’ events, but fortunately not of ‘fatal bleeding’ or ‘critical organ bleeding’.7,8

These data exemplify the conflict between the benefit and potential harm of therapeutic interventions, demanding high standards in clinical routine and daily medical practice, and including a thorough evaluation of each single patient with regard to the individual risk, compliance and treatment adherence. These ideal conditions are usually guaranteed in high standard prospective randomised trials but not necessarily in all day care. Therefore, additional checks of new regimens on top of well-established therapies on their effectiveness and added benefit are warranted. Well performed prospective registries reflecting clinical
practice and professionally performed cost-effectiveness evaluations may provide this important additional information relevant for decision-making in all day care.

Cost-effectiveness analysis, benefit and limitations of DPI

Against this background and based on data from the COMPASS trial\(^7,8\) and a willingness to pay of €50,000, Petersohn et al. tested the cost effectiveness of DPI compared to aspirin alone in CAD, and clopidogrel alone in PAD patients following a sophisticated state transition model thereby including cardiovascular, ischaemic limb and bleeding events.\(^9\) The cost-effectiveness probability of DPI was 92% in CAD patients, but only 56% in patients with PAD. DPI was especially cost-effective in young CAD patients and in PAD patients with existing comorbidities. In contrast, DPI was neither cost-effective in patients with carotid artery disease nor in older CAD patients more than 75 years of age.\(^9\) This ambitious cost-effectiveness evaluation therefore confirms the baseline beneficial prognostic impact of DPI in patients with stable CAD and stable PAD, but also demonstrates well-defined limitations of this therapeutic regimen to be considered in clinical all day care and future research.

Cost-effectiveness of DPI and clinical all day care reality

The cost-effectiveness of DPI in patients with stable CAD and stable PAD is based on the well-defined population of the COMPASS trial being followed for 21 (median) or 23 (mean) months.\(^7,8\) The majority of the study population received guideline-adjusted medication for secondary prevention. However, approximately 27% (PAD) and 21% (CAD) of the participating patients were still current smokers.\(^7,8\) Smoking, however, augments platelet activation/aggregation and supports activation of the endothelial-coagulative system.\(^10\)\(^-\)\(^13\) This special risk group of current smokers therefore might especially benefit from DPI, but the preferred way would be simply to quit smoking life long, thereby favourably shifting cost-effectiveness evaluations.

These considerations cast light on a still unsolved major problem. Neither in primary nor in secondary prevention have lifestyle adaption and guideline-adjusted medication been followed to a sufficient degree for decades.\(^14\)\(^,\)\(^15\) This problem is underscored by the observation that a large proportion of CAD patients in Europe do not achieve recommended treatment targets due to incomplete medication intake.\(^16\) These considerable baseline deficits in prevention may therefore counteract sophisticated ‘on top’ improvements in drug regimen, and thereby also affect cost-effectiveness measures. On the other hand, the consequent utilisation of well-structured and supervised prevention and rehabilitation programmes will help to enforce prevention strategies and thereby also help to introduce innovative therapies sustainably in clinical all day care.\(^7\)\(^-\)\(^19\)

‘From the top back to baseline’

When writing this editorial COVID-19 threatens every country all over the world. At this time neither effective vaccination nor targeted therapeutic options are available, but patients with CVD and/or diabetes are known to be of special risk of dying from Sars-CoV-2 infection.\(^20\)\(^,\)\(^21\) This situation may even be aggravated by the fact that new antiviral drugs being developed to treat Sars-CoV-2 infection need to be tested against potentially negative interactions with current cardio-protective medication, including antiplatelet drugs and novel anticoagulants.\(^22\) This exceptional situation greatly interfering with our social and personal lives therefore strongly reminds us to do everything needed for disease prevention, and to do this in time. Disease prevention will thereby be the most cost-effective approach to save our lives and social living sustainably.

Acknowledgement

The author would like to thank Professor Dr. med. Ursula Gundert-Remy, Arzneimittelkommission der Deutschen Ärzteschaft (ÄKdÄ), who critically followed this review from the pharmacologist’s viewpoint.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Anand SS and Yusuf S.; for the Warfarin Antiplatelet Vascular Evaluation Trial Investigators, WAVE. Oral anticoagulants and antiplatelet therapy and peripheral arterial disease. *N Engl J Med* 2007; 357: 217–227.
2. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* 2006; 354: 1706–1717.
3. Bonoca MP, Bhatt DL, Cohen M, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015; 372: 1791–1800.

4. Hiatt WR, Fowkes FGR, Heizer G, et al.; for the EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. *N Engl J Med* 2017; 376: 32–40.

5. Morrow DA, Braunwald E, Bonoca MP, et al.; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. *N Engl J Med* 2012; 366: 1404–1413.

6. Mega JL, Braunwald E, Wiviott SD, et al.; for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med* 2012; 366: 9–19.

7. Eikelboom JW, Connolly SJ, Bosch J, et al.; for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med* 2017; 377: 1319–1330.

8. Anand SS, Bosch J, Eikelboom JW, et al.; on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 2018; 391: 219–229.

9. Petersohn S, Pouwels X, Ramaekers B, et al. Rivaroxaban plus aspirin for the prevention of ischemic events in patients with cardiovascular disease: a cost-effectiveness study. *Eur J Prev Cardiol* 2020; 27: 1354–1365.

10. Ichiki K, Ikeda H, Haramaki N, et al. Long-term smoking impairs platelet-derived nitric oxide release. *Circulation* 1996; 94: 3104–3114.

11. Nocella C, Biondi-Zoccai G, Scarretta S, et al. Impact of tobacco versus electronic cigarette smoking on platelet function. *Am J Cardiol* 2018; 122: 1477–1481.

12. Swaminathan A, Amikumpur K, Ganapathy S, et al. Evaluation of the impact of cigarette smoking on platelet parameters. *Natl J Physiol Pharm Pharmacol* 2015; 5: 426–430.

13. Takajo Y, Ikeda H, Haramaki N, et al. Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. *J Am Coll Cardiol* 2001; 38: 1320–1327.

14. Kotseva K, De Backer G, De Bacquier D, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational research Programme EUROASPIRE V survey in 16 European countries. *Eur J Prev Cardiol*, Epub ahead of print 20 March 2020. DOI: 10.1177/2047487320908698.

15. Kotseva K, De Backer G, De Bacquier D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol* 2019; 26: 824–835.

16. De Smidt D, De Backer T, Petrovic M, et al. Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. *Int J Cardiol* 2020; 300: 7–13.

17. Rauch B, Davos CH, Doherty P, et al.; on behalf of the “Cardiac Rehabilitation Section”, European Association of Preventive Cardiology (EAPC). The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). *Eur J Prev Cardiol* 2016; 23: 1914–1939.

18. Salzwedel A, Jensen K, Rauch B, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). *Eur J Prev Cardiol*, Epub ahead of print 23 February 2020. DOI: 10.1177/2047487320905719.

19. Gysan D, Millentrup S, Albus C, et al. Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: a randomized trial: the Preford-Study. *Eur J Prev Cardiol* 2017; 24: 1544–1554.

20. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*, Epub ahead of print 12 March 2020. DOI: 10.1016/j.ijid.2020.03.017.

21. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*, Epub ahead of print 27 March 2020. DOI: 10.1001/jamacardio.2020.1017.

22. Egan G, Hughes CA and Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. *Ann Pharmacother* 2014; 48: 734–740.